Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now

UPDATE 2-Chinese investor group buying control of Australia's Nature's Care

Published 11/04/2018, 09:05 pm
© Reuters.  UPDATE 2-Chinese investor group buying control of Australia's Nature's Care

* Buyers are JIC, its unit and Tamar Alliance fund

* Nature's Care is Australia's 3rd largest vitamin company

* Company valued at about A$800 mln in deal - source

By Paulina Duran and Pei Li

SYDNEY/BEIJING, April 11 (Reuters) - A Chinese state-backed consortium is snapping up a majority stake in Australian vitamin company Nature's Care, valuing the firm at around A$800 million ($619.92 million), the latest in a string of deals led by China for global nutrition assets.

The consortium includes investment group China Jianyin Investment Ltd (JIC), one of its subsidiaries and private equity fund Tamar Alliance, according to Nature's Care and the buyers who issued a joint statement on Wednesday. The financial details of the deal were not disclosed.

A source with direct knowledge of the deal, however, said the acquisition values the Sydney-based vitamin firm at about A$800 million.

Nature's Care is Australia's third largest vitamin company and also manufactures supplements and skin care products. Its founders and current owners, the Sydney-based Wu family, will retain the remaining minority stake in the 28-year-old company, two further sources told Reuters.

All three sources declined to be identified because the details of the deal were private.

Nature's Care did not immediately reply to an email seeking comment about the deal value and could not be reached by phone.

Chinese investors have been hunting for deals in health foods, vitamins and supplements overseas to meet growing demand from China's burgeoning middle class who are becoming increasingly health and fitness conscious.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Australian firms in the sector including Swisse Wellness and Vitaco Holdings have lured Chinese buyers in recent years, while Chinese drugmaker Harbin Pharmaceutical Group Holding Co 600664.SS said it would buy a 40 percent stake in U.S. nutritional supplements maker GNC in February. is a lot of room for growth in China," said Ben Cavender, Shanghai-based principal at China Market Research Group, who added that Australian firms especially had built up good cachet and brand awareness in China.

The buying consortium added in their statement that there was "explosive growth" in Chinese demand for "high quality nutrition supplements from overseas countries like Australia", helped in part by a flourishing cross-border online market.

The deal is subject to regulatory approvals and is expected to close in the second half of 2018, the statement said. UBS advised Nature's Care, while Deutsche Bank (DE:DBKGn) advised the buying consortium, the statement said.

The Australian Financial Review reported the deal earlier on Wednesday.

JIC is one of China's largest state-owned funds. Its portfolio of investments included medical care, artificial intelligence chips and book stores. Tamar Alliance is owned by Citic Pacific Ltd and Dah Chong Hong Holdings 1828.HK .

($1 = 1.2905 Australian dollars)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.